Yongbao Zhu

This inventor holds 19 USPTO granted patents and 8 published patent applications, plus 6 CIPO patents and 11 EPO patents, primarily in Glycosidase Inhibitors. Top assignees: Alectos Therapeutics Inc., Merck Sharp + Dohme Corp., Genzyme Corporation. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yongbao Zhu. Retrieved from https://idiyas.com/inventor/yongbao-zhu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 8)

% Patents Active = 57.9

CIPO Patents = 6 (Patent Applications = 3)

EPO Patents = 11 (Patent Applications = 9)

Average Co-Inventor Count = 7.2

ph-index = 6

Forward Citations = 154(Granted Patents)

Location History:

Coquitlam, CA (2007 - 2011)
Langley, CA (2010 - 2015)
Burnaby, CA (2015 - 2018)

Company Filing History:

10 out of 19

Alectos Therapeutics Inc.

patents

8 out of 2,405

Merck Sharp + Dohme Corp.

Zalicus Pharmaceuticals, Ltd.

patents

5. 1 out of 157

Simon Fraser University

patents

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

Glycosidase Inhibitors

Chemokine Receptor Binding

Calcium Channel Blockers

Glucocerebrosidase Modulators

Selective Inhibitors

Non-Lysosomal Inhibitors

Heterocyclic Compounds

Chemical Compounds

CXCR4 Compounds

Piperidinyl Derivatives

Receptor Binding

Modulators

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12528773 - NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF (2026-01-20),

2. 10081601 - Glucocerebrosidase modulators and uses thereof (2018-09-25),

3. 9815861 - Selective glycosidase inhibitors and uses thereof (2017-11-14),

4. 9809537 - Glycosidase inhibitors and uses thereof (2017-11-07),

5. 9796680 - Glucocerebrosidase modulators and uses thereof (2017-10-24),

6. 9701693 - Selective glycosidase inhibitors and uses thereof (2017-07-11),

7. 9409924 - Selective glycosidase inhibitors and uses thereof (2016-08-09),

8. 9243020 - Selective glycosidase inhibitors and uses thereof (2016-01-26),

9. 9126957 - Selective glycosidase inhibitors and uses thereof (2015-09-08),

10. 9120781 - Selective glycosidase inhibitors and uses thereof (2015-09-01),

11. 9096522 - N-piperidinyl acetamide derivatives as calcium channel blockers (2015-08-04),

12. 8901087 - Selective glycosidase inhibitors and uses thereof (2014-12-02),

13. 8569344 - N-piperidinyl acetamide derivatives as calcium channel blockers (2013-10-29),

14. 8377968 - N-piperidinyl acetamide derivatives as calcium channel blockers (2013-02-19),

15. 7863293 - CXCR4 chemokine receptor binding compounds (2011-01-04),

Title: Yongbao Zhu: Innovator in Glycosidase Modulation

Introduction

Yongbao Zhu is a prominent inventor based in Langley, CA, known for his significant contributions to the field of glycosidase modulation. With a total of 18 patents to his name, Zhu has made remarkable advancements in pharmaceutical compositions and treatments related to glycosidases.

Latest Patents

Among his latest patents, Zhu has developed "Glucocerebrosidase modulators and uses thereof," which provides compounds for modulating glycosidases, including prodrugs and pharmaceutical compositions. Another notable patent is "Selective glycosidase inhibitors and uses thereof," which focuses on compounds with enhanced permeability for selectively inhibiting glycosidases. This invention also outlines methods for treating diseases and disorders associated with the deficiency or overexpression of O-GlcNAcase, as well as the accumulation or deficiency of O-GlcNAc.

Career Highlights

Zhu has worked with notable companies such as Alectos Therapeutics Inc. and Merck Sharp & Dohme Corporation, where he has applied his expertise in glycosidase modulation to develop innovative therapeutic solutions.

Collaborations

Zhu has collaborated with esteemed colleagues, including Yuanxi Zhou and Ernest John McEachern, contributing to the advancement of research in his field.

Conclusion

Yongbao Zhu's work in glycosidase modulation has led to significant innovations in pharmaceutical treatments, showcasing his dedication to advancing medical science. His contributions continue to impact the field positively.

Profile summary based on public USPTO records.